Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy

Table 2

Overview of the clinical patient data. 20 of 21 patients show concordance of the KRAS (exon 2, Gly 12/13) and BRAF (exon 15, V600E) mutation status between samples of primary CRCs and/or corresponding metastases before and after combined cetuximab therapy. In one case (#4), the primary CRC had a mutated KRAS gene (Gly12Asp), while the liver metastasis biopsied after combined cetuximab therapy showed a 𝐾𝑅𝐴𝑆^𝑤𝑡 genotype. BRAF mutation status in this case was concordant between the samples gathered before and after anti-EGFR therapy.

Case no.	Sex/Age	Date and localisation of tumor manifestaion	KRAS Gly12/13 (exon2)	BRAF V600E (exon15)	Anti-EGFR therapy
1	M/51 y	09/05 primary CRC	Gly12Val	WT	01/07–04/07 Folfiri/Cetuximab (PD)
		11/07 small bowel metastasis	Gly12Val	WT	dead 05/08
2	M/71 y	11/02 soft tissue	Gly12Cys	WT	09/04–08/05 Folfiri/Cetuximab (PR)
		03/06 mesocolon transversum metastasis	Gly12Cys	WT
3	M/46 y	03/07 primary CRC	WT	WT	08/07–06/08 Folfiri/Cetuximab (PR)
		02/09 peritoneal carcinosis	WT	WT
4	M/68 y	11/06 primary CRC	Gly12Asp	WT	04/07–02/08 Fufox/Cetuximab(PR)
		03/08 liver metastasis	WT	WT
5	F/56 y	07/08 primary CRC	Gly12Asp	WT	07/08–09/08 Fufox/Cetuximab (PD)
		12/08 peritoneal carcinosis	Gly12Asp	WT	dead 12/08
6	M/71 y	12/05 primary CRC	Gly12Val	WT	01/06–07/06 Folfiri/Cetuximab (PD)
		12/06 liver metastasis	Gly12Val	WT	dead 04/08
7	F/58 y	01/08 primary CRC	WT	WT	04/08–07/08 Folfiri/Cetuximab (PD)
		07/08 peritoneal carcinosis	WT	WT	dead 07/08
8	F/44 y	11/07 primary CRC	WT	WT	05/08–03/09 Folfox/Cetuximab (PR)
		12/08 peritoneal carcinosis	WT	WT
9	F/66 y	02/04 primary CRC	Gly12Ser	WT	07/06–09/06 Folfox/Cetuximab (PR)
		11/05 + 04/06 liver metastasis	Gly12Ser	WT	07/06–09/06 Folfox/Cetuximab (PD)
		11/06 lung metastasis	Gly12Ser	WT	09/06-11/06 Folfiri/Avastin (PD)
10	M/77 y	11/05 primary CRC	Gly13Asp	WT	12/05–09/06 Folfox + Cetuximab (PD)
		07/06 lymph node	Gly13Asp	WT	10/06–02/07 Folfiri + Avastin (PD) dead 05/07
11	M/63 y	05/07primary CRC	WT	WT	05/07–07/08 Folfiri/Cetuximab (PR)
		01/08 liver metastasis	WT	WT	10/08–05/09 Folfox (PR)
		06/09 liver metastasis	WT	WT
12	M/67 y	07/07 liver metastasis	WT	WT	08/07–04/08 Folfox/Cetuximab (PR)
		01/08 liver metastasis	WT	WT
13	M/59 y	09/07 primary CRC	WT	WT
		10/07 liver metastasis	WT	WT	11/07–03/08 Folfiri/Cetuximab (PR)
		05/08 liver metastasis	WT	WT
14	M/61 y	07/02 primary CRC	WT	WT	10/07–07/08 Folfox/Cetuximab (PR)
		05/04 liver metastasis	WT	WT
		07/08 peritoneal carcinosis	WT	WT	Since 12/08 Folfox (PR)
15	F/68 y	09/05 primary CRC	WT	V600E	10/05–02/06 Folfox (PD)
		05/06 soft tissue	WT	V600E	03/06–08/06 Folfiri/Cetuximab (PR)
		01/07 soft tissue	WT	V600E	01/07–05/07 Cetuximab/Irinotecon (PD) dead 06/07
16	M/75 y	07/00 primary CRC	Gly12Asp	WT
		07/03 lung metastasis	Gly12Asp	WT	08/03–07/04 Folfox (PD)
		08/03 liver metastasis			08/04–08/05 Folfiri (PD)
		08/05 liver metastasis	Gly12Asp	WT	08/05–04/06 Folfiri/Cetuximab (PD) 04/06–02/07 Cetuximab+CPT-11(PD)02/07–04/07 Panitumumab (PD)
		04/07 ascites	Gly12Asp	WT	dead 05/07
17	M/69 y	06/02 primary CRC	Gly13Asp	WT	06/02–09/02 Folfox (PR) 06/03–12/03 Folfox (PR) 07/04–01/06 Folfiri (PD) 03/06–05/06 Cetuximab + CPT-11 (PD) 09/06–02/07 Folfox (PD)
		07/07 mesocolon metastasis	Gly13Asp	WT	dead 09/07
18	M/75 y	01/04 primary CRC	Gly12Asp	WT	06/07–10/07 Capecitabine/Cetximab (PD)
		01/08 peritoneal carcinosis	Gly12Asp	WT	dead 03/08
19	F/61 y	07/08 primary CRC	WT	WT	07/08–03/09 Folfiri/Cetuximab (PR)
		05/09 liver metastasis	WT	WT
20	M/56 y	05/08 primary CRC	WT	WT	06/08-12/08 Folfox/Cetuximab (PR)
		06/09 lung metastasis	WT	WT
21	M/72 y	09/08 primary CRC	WT	WT	10/08-02/09 Folfiri/Cetuximab (PR)
		01/09 liver metastasis	WT	WT

Response evaluation (according to RECIST criteria): PD: progressive disease; SD: stable disease; PR: partial remission; CR: complete remission.